22 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 29 Phase 2, 6 Phase 1, 1 Phase 3.
Follow Dysentery: new trials by email Literature Review of Dysentery trials Research Report on Dysentery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants 30μg IP-QSV, Placebo, 10μg IP-QSV - Shigella Infection | Phase 1 / Phase 2 | Not yet recruiting | International Vaccine Institute | 370 | 2026-07-01 | 2026-06-24 |
| The Impact of Shigellosis and Recommended Treatment in Children Azithromycin, Placebo - Diarrhea Infectious, Shigella | Phase 2 | Recruiting | Johns Hopkins Bloomberg School of Public Health | 700 | 2026-03-18 | 2026-03-30 |
| Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU - Shigella | Phase 2 | Recruiting | Eveliqure Biotechnologies GmbH | 72 | 2025-06-30 | 2025-07-08 |
| Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. Shigella4V2, MenACWY - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 110 | 2025-04-07 | 2026-08-07 |
| A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants altSonflex1-2-3 Dose A, altSonflex1-2-3 Dose B, altSonflex1-2-3 Dose C - Diarrhoea | Phase 2 | Completed | GlaxoSmithKline | 200 | 2024-11-13 | 2026-10-26 |
| A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine Shigella4V2, Placebo - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 97 | 2024-11-12 | 2026-10-01 |
| Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model. Travelan, Placebo - Diarrhea, Travelers Diarrhea | Phase 2 | Completed | Immuron Ltd. | 63 | 2023-05-29 | 2026-06-12 |
| Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis bacteriophage, Placebo - Shigellosis | Phase 1 / Phase 2 | Active not recruiting | Intralytix, Inc. | 52 | 2023-02-23 | 2025-06-15 |
| Phase 2 Shigella Vaccine and Challenge Placebo, Shigella sonnei strain 53G, WRSs2 - Immunisation, Shigella Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 69 | 2022-10-12 | 2026-08-10 |
| Tebipenem Trial in Children With Shigellosis Tebipenem Pivoxil, Azithromycin, Ceftriaxon - Shigellosis | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 132 | 2022-08-18 | 2026-09-01 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a Injection SF2A-TT15 10 µg Adjuvanted, Injection SF2A-TT15 10 µg, Injection Adjuvanted Placebo - Healthy | Phase 2 | Completed | Institut Pasteur | 248 | 2020-10-06 | 2024-04-23 |
| Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent - Shigella | Phase 2 | Completed | University of Maryland, Baltimore | 58 | 2020-03-02 | 2024-05-20 |
| A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Shigella 4V, MenACWY, Rabies - Shigellosis | Phase 1 / Phase 2 | Completed | LimmaTech Biologics AG | 597 | 2019-09-02 | 2026-06-23 |
| Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine, Haemophilus b Conjugate Vaccine - Dysentery, Dysentery, Bacillary | Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1050 | 2019-01-19 | 2022-01-13 |
| A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults S.sonnei vaccine, Placebo, S. sonnei 53G challenge strain - Dysentery, Bacillary | Phase 2 | Completed | GlaxoSmithKline | 71 | 2018-08-29 | 2020-07-28 |
| Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine, Placebo - Shigella Sonnei Dysenteries | Phase 2 | Withdrawn | PATH | 2017-08-01 | 2017-11-20 | |
| Auranofin for Giardia Protozoa Auranofin, Placebo - Amoebic Dysentery, Giardiasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 93 | 2016-11-06 | 2023-01-26 |
| Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Flexyn2a, Placebo - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 67 | 2015-12-01 | 2021-01-27 |
| Efficacy of Rifaximin in Preventing Campylobacteriosis Rifaximin intervention, Placebo intervention - Dysentery, Diarrhea | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 30 | 2014-10-01 | 2018-11-20 |
Showing 20 of 29. Sign in to see all of them.
Dysentery, Bacillary (23) · Diarrhea (6) · Enterocolitis, Pseudomembranous (2) · Amebiasis (1) · Campylobacter Infections (1) · Dysentery, Amebic (1) · Giardiasis (1)
Digestive System Diseases (29) · Gastroenteritis (29) · Gastrointestinal Diseases (29) · Intestinal Diseases (29) · Infections (27) · Bacterial Infections (26) · Bacterial Infections and Mycoses (26) · Gram-Negative Bacterial Infections (24) · Enterobacteriaceae Infections (23) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Signs and Symptoms, Digestive (6) · Clostridium Infections (2) · Enterocolitis (2)
Azithromycin (2) · MenACWY (2) · Tetanus Toxoid (2) · Vaccines (2) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (2) · Aluminum Hydroxide (1) · Auranofin (1) · Boostrix (1) · Butyric Acid (1) · Ceftriaxone (1) · Hepatitis B Vaccines (1) · HibTITER protein, Haemophilus influenzae (1) · L 084 (1) · Meningococcal Vaccines (1) · Rubella Vaccine (1)
LimmaTech Biologics AG (4) · GlaxoSmithKline (3) · University of Maryland, Baltimore (3) · Genzyme, a Sanofi Company (2) · Institut Pasteur (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · Johns Hopkins Bloomberg School of Public Health (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · U.S. Army Medical Research and Development Command (2) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Cosmo Technologies Ltd (1) · Eveliqure Biotechnologies GmbH (1) · Immuron Ltd. (1) · International Vaccine Institute (1) · Intralytix, Inc. (1)
United States (14) · Kenya (5) · Bangladesh (4) · Canada (2) · United Kingdom (2) · Belgium (1) · China (1) · France (1) · Puerto Rico (1) · Thailand (1) · Zambia (1)
Karen L Kotloff, M.D. (2) · Kawsar R Talaat, MD (2) · Alexander Sulakvelidze, PhD (1) · Armelle Phalipon, PhD (1) · Carl Mason, MD (1) · Christiane Gerke, PhD (1) · Dr David Lewis, MD (1) · Dr Odile Launay, MD (1) · Fredrick Sawe, MBChB MMED (1) · Josphat Kosgei, MD (1) · Kawsar Talaat, M.D. (1)
PMID 11692292, PMID 12809830, PMID 15017618, PMID 17382603, PMID 18809665, PMID 19842970, PMID 20086085, PMID 20412178, PMID 21050319, PMID 21896097, PMID 22574737, PMID 22864805, PMID 23840001, PMID 27146000, PMID 29145631, PMID 33862589, PMID 35062694, PMID 38853614, PMID 40000088, PMID 42379208, PMID 42617627
U01AI179562 (1)